Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03308669 · ClinicalTrials.gov registry record · Phase 1
A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03308669 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 30 participants.
The verdict
NCT03308669, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability and blood concentrations of lasmiditan and topiramate together compared to lasmiditan and topiramate separately. Information about any side effects that may occur will be collected. Participants will be admitted to the Clinical Research Unit (CRU) one day prior to the start of the study and will remain through Day 14. This study is expected to last approximately 25 days, not including screening. Screening is required within 28 days prior to the start of the study.
Interventions
- DRUG Placebo
- DRUG Topiramate
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2017-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03308669
The ClinicalTrials.gov registry entry for NCT03308669 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03308669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03308669 about?
NCT03308669 is a clinical study titled "A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate". This study will assess the safety, tolerability and blood concentrations of lasmiditan and topiramate together compared to lasmiditan and topiramate separately. Information about any side effects that may occur will be collected. Participants will be admitted to the Clinical Research Unit (CRU) one...
What is the current status of trial NCT03308669?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-10-16. Estimated completion is 2017-12-02.
What interventions are being tested in trial NCT03308669?
The interventions under investigation include: Placebo (DRUG), Topiramate (DRUG), Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT03308669?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.